Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinicians aren’t the only ones parsing dense study tables: investors trying to locate R&D burn or pivotal-trial milestones inside Palvella Therapeutics� SEC disclosures face the same hurdle. Whether you’re scanning the company’s QTORIN® platform updates or gauging cash runway before the next phase 3 read-out, every detail is hidden across multiple forms. Stock Titan turns that complexity into clarity by delivering Palvella Therapeutics SEC filings explained simply, complete with plain-language AI summaries minutes after each document hits EDGAR.
Type a natural question—“How do I read the Palvella Therapeutics annual report 10-K?� or “Where are Palvella Therapeutics insider trading Form 4 transactions?”—and our engine surfaces the answer. You’ll receive real-time alerts for Palvella Therapeutics Form 4 insider transactions real-time and concise takeaways from every Palvella Therapeutics quarterly earnings report 10-Q filing. Key filings are decoded so you can:
- Track pipeline progress via Palvella Therapeutics 8-K material events explained by AI
- Spot executive stock moves through Palvella Therapeutics executive stock transactions Form 4
- Review board pay inside the Palvella Therapeutics proxy statement executive compensation section
- Compare cash usage and trial spend with Palvella Therapeutics earnings report filing analysis
- Download the Palvella Therapeutics annual report 10-K simplified for quick reference
Behind every headline number, Stock Titan’s AI pinpoints what matters for a clinical-stage biotech: dilution risk from follow-on offerings, milestone-based licensing revenues, and the pace of enrollment for rare-disease studies. Understanding Palvella Therapeutics SEC documents with AI means you see how QTORIN® formulation costs translate into future margins and how insider sentiment aligns with pending data releases. Stop wading through technical jargon—view, search, and act on every disclosure the moment it is filed.
Palvella Therapeutics, Inc. (PVLA) disclosed a Schedule 13G/A reporting that Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju together beneficially own 339,743 shares of common stock, representing 3.1% of the class based on 11,055,665 shares outstanding as of May 9, 2025. The filing states Samsara LP directly holds the shares, Samsara GP is the general partner and Dr. Akkaraju is a managing member, and that the holdings were not acquired to change or influence control of the issuer.
The filing is dated for the reporting event as of June 30, 2025 and signatures show execution on August 14, 2025. The reporting address is c/o Samsara BioCapital, LLC, Palo Alto, CA.
Frazier Life Sciences and affiliated funds report their holdings in Palvella Therapeutics, Inc. common stock. Frazier Life Sciences Public Fund, L.P. (FLSPF) directly holds 545,504 shares, which the filing states represents 4.9% of the 11,055,665 shares of common stock used for the percentage calculation. Other Frazier vehicles reported include holdings of 160,856, 7,517, 4,730 and 3,793 shares, with sole voting and dispositive power reported as 0 and shared power reported where indicated.
The filing corrects prior attributions by stating members of certain investment committees are not attributed beneficial ownership of fund-held securities. It also discloses prefunded warrants: FLSPF holds warrants to purchase 937,965 shares, FLSPOF 276,766, FLS X 5,641 and FLS XI 5,886, each subject to exercise limits preventing the holder from exceeding 4.99% beneficial ownership after exercise. The statement clarifies ownership, voting and dispositive arrangements among the reporting persons.
Palvella Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on topical QTORIN rapamycin for rare genetic skin diseases. At June 30, 2025 the company held $70.4 million in cash and cash equivalents, total assets of $73.7 million and an accumulated deficit of $111.4 million. For the six months ended June 30, 2025 Palvella reported a net loss of $17.7 million driven by total operating expenses of $17.1 million (R&D and G&A).
The company completed a reverse merger and related PIPE financing that provided substantial capital; management states existing cash is sufficient to support operations through at least one year from issuance of these statements assuming no additional fundraising. Key balance sheet items include a $14.5 million royalty agreement liability and Level 3 derivative liabilities for the royalty agreement and contingent value rights totaling $3.8 million. Clinical progress includes completion of enrollment in the Phase 3 SELVA trial (51 subjects), dosing in the Phase 2 TOIVA trial, receipt of an initial $0.5 million FDA grant, and a newly granted U.S. patent for anhydrous rapamycin formulations.
Palvella Therapeutics, Inc. reported that on August 14, 2025 it announced financial results for the quarter ended June 30, 2025. The company furnished a press release and an earnings-call slide presentation as Exhibits 99.1 and 99.2 to this Current Report, and will hold an earnings call using the presentation on the same date. The filing explicitly states that the materials are being furnished rather than "filed," so they are not subject to the liabilities of Section 18 of the Exchange Act and are not automatically incorporated by reference into other SEC filings.
The report provides notice of the release and the investor presentation but does not include financial figures, results detail, or forward-looking guidance within the 8-K text itself; investors must consult the furnished press release and presentation for substantive financial information.
FAQ
What is the current stock price of Palvella Therapeutics (PVLA)?
What is the market cap of Palvella Therapeutics (PVLA)?
